ALKS

Alkermes plc

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$569.4M

Burn Rate (Qtr)

$0.1M

Company Profile

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Aristada (aripiprazole lauroxil)

Schizophrenia in adults

Quarterly Sales (Approved)

Feb 12, 2020 (Est.)

Vivitrol (naltrexone)

Alcohol dependence and opioid dependence treatment

Quarterly Sales (Approved)

February 12, 2021 (Est)

ALKS 3831

Schizophrenia, bipolar

Resubmit NDA

TBD

ALKS 4230

Solid Tumors

Phase 2 Readout

September 2021

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon